R&D channel feed

Boehringer fol­lows the pop­u­lar KRAS trail to MD An­der­son — inks new al­liance on 'vir­tu­al' re­search cen­ter

6 years ago
Deals

Key Ap­ple dig­i­tal health re­searcher set to join the Gates Foun­da­tion — re­port

6 years ago
People

Top Scripps sci­en­tist and biotech co-founder makes an abrupt — and un­ex­plained — ex­it

6 years ago

Ap­ple de­vices, in tan­dem with dig­i­tal apps, could de­tect ear­ly signs of Alzheimer's, de­men­tia: study

6 years ago

As­traZeneca's flag­ship Tagris­so helps lung can­cer pa­tients live longer in piv­otal study

6 years ago
Pharma

Mys­tery solved? Nek­tar chief says 'soft­en­ing' in pa­tient re­spons­es to be­m­peg was a CMC is­sue — spurring a rout

6 years ago

The FDA de­cides to hold an ex­pert pan­el re­view of Vas­cepa af­ter all — and Amarin shares tank on un­ex­pect­ed de­lay

6 years ago
FDA+

Sarep­ta shares slammed on re­port gene ther­a­py Duchenne MD pa­tient was hos­pi­tal­ized, but the com­pa­ny says it is 'er­ro­neous'

6 years ago
Pharma

New ex­ec team, new mon­ey and a big syn­di­cate — ORIC heads to PhII

6 years ago

FDA Ad­Com backs Gilead­'s move to ex­pand De­scovy la­bel — but stops short of en­dors­ing broad PrEP use

6 years ago
Pharma

What’s a late-stage IL-23 drug worth these days? We’re about to find out

6 years ago
Pharma

As­traZeneca, Mer­ck her­ald PhI­II prostate can­cer win for Lyn­parza — over­tak­ing Clo­vis, J&J in PARP race

6 years ago
Pharma

Rhythm Phar­ma­ceu­ti­cal­s' lead drug scores in piv­otal rare obe­si­ty tri­als

6 years ago

Gilead faces a hur­dle in its race for big, add-on OK for De­scovy as gener­ic Tru­va­da ri­vals loom

6 years ago
Pharma

Glax­o­SmithK­line drops out of Ebo­la vac­cine de­vel­op­ment as R&D shifts re­sources to fran­chise drugs

6 years ago

Sanofi, Re­gen­eron post back-to-back wins with new OK and a fresh round of pos­i­tive PhI­II da­ta for their block­buster growth fran­chise

6 years ago

Tiny Si­en­na is call­ing in Cowen as shares con­tin­ue to lan­guish long af­ter a se­vere tri­al set­back

6 years ago

Close to a decade af­ter Eli Lil­ly killed it, Jef­frey Blue­stone's 'break­through' drug is back and be­ing steered to the FDA

6 years ago
FDA+

Roche scores a no­table PhI­II suc­cess with Tecen­triq com­bo in blad­der can­cer, but is this an­oth­er case of too lit­tle too late?

6 years ago
Pharma

Gly­coMimet­ics shares crash af­ter Pfiz­er team dis­miss­es their lead drug as a PhI­II fail­ure

6 years ago

Salk sci­en­tists cre­ate the world’s first hu­man/mon­key chimeras in Chi­na — cue the con­tro­ver­sy

6 years ago

Ko­re­an biotech sees shares blitzed as its on­colyt­ic virus/Nex­avar com­bo fiz­zles in liv­er can­cer

6 years ago

Bio­Marin ex­ecs make their case for he­mo­phil­ia gene ther­a­py as fret­ful an­a­lysts start to hedge their bets

6 years ago

Still trail­ing far be­hind a block­buster ri­val, No­var­tis gath­ers an­oth­er round of pos­i­tive sur­vival da­ta for Kisqali

6 years ago
First page Previous page 236237238239240241242 Next page Last page
A service from the Financial Times